SELLAS Life Sciences raised $28.7M from warrant exercises in Apr-May 2026

SELLAS Life Sciences Group, Inc.

Received approximately $28.7 million in proceeds from warrant exercises during April and May 2026.
Cash and cash equivalents were $107.1 million as of March 31, 2026; now increased by warrant proceeds.
Common shares outstanding as of June 2, 2026: 196,632,574.
No other material events disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.